# Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

> **NCT06151730** · — · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 100 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Hematopoietic and Lymphoid System Neoplasm
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Waldenstrom Macroglobulinemia

## Interventions

- **OTHER:** Non-Interventional Study

## Key facts

- **NCT ID:** NCT06151730
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-05
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06151730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06151730, "Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06151730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*